EFPIA：2026年欧洲国家需要用国家层面的新型抗菌药物规定，来补充欧盟层面的拉动性激励措施报告（英文版）

Antimicrobial resistance (AMR) poses an escalating threat to global health, economies, and healthsystem resilience.1 Resistant infections already cause more than 35,000 deaths annually in Europe and cost billions in healthcare and productivity losses.2 The urgent need for new antibiotics to be developed is widely acknowledged; at the same time, the antibiotic market fails to provide adequate incentives for innovation. Although the clinical need for new antimicrobials is well established, the